SAT-300-Prospective liver biopsy-based prevalence of non-alcoholic fatty liver disease and steatohepatitis among a large middle-aged population utilizing FibroScan, LiverMultiscan and magnetic resonance elastography to guide liver biopsy

2019 ◽  
Vol 70 (1) ◽  
pp. e770-e771
Author(s):  
Stephen Harrison ◽  
Katharine Roberts ◽  
Christopher Lisanti ◽  
Ryan Schwope ◽  
Katherine Cebe ◽  
...  
Keyword(s):  
Liver Disease ◽  
Magnetic Resonance ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Magnetic Resonance Elastography ◽  
Middle Aged ◽  
Alcoholic Fatty Liver ◽  
Aged Population ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study)

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142937 ◽  
Author(s):  
Aki J. Käräjämäki ◽  
Olli-Pekka Pätsi ◽  
Markku Savolainen ◽  
Y. Antero Kesäniemi ◽  
Heikki Huikuri ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Middle Aged ◽  
Alcoholic Fatty Liver ◽  
Aged Population ◽  
Alcoholic Fatty Liver Disease

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease

2020 ◽  
Vol 26 (32) ◽  
pp. 3928-3938
Author(s):  
Grazia Pennisi ◽  
Ciro Celsa ◽  
Antonina Giammanco ◽  
Federica Spatola ◽  
Salvatore Petta
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Assessment Tools ◽  
Hepatic Decompensation ◽  
Alcoholic Fatty Liver ◽  
Simple Steatosis ◽  
Life Threatening ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, involving about 25% of people. NAFLD incorporates a large spectrum of pathological conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and its complications include hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in an asymptomatic way, until advanced fibrosis appears. Thus, the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis are key issues. To date, the histological assessment of fibrosis with liver biopsy is the gold standard, but obviously, invasiveness is the greater threshold. In addition, rare but potentially life-threatening complications, poor acceptability, sampling variability and cost maybe restrict its use. Furthermore, due to the epidemic of NAFLD worldwide and several limitations of liver biopsy evaluation, noninvasive assessment tools to detect fibrosis in NAFLD patients are needed.

Sign in / Sign up

Export Citation Format

Share Document